• 1
    Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 9921002.
  • 2
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 13351374.
  • 3
    Brau N, Salvatore M, Rios-Bedoya CF et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 4755.
  • 4
    Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271278.
  • 5
    Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: F27F36.
  • 6
    Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 28392848.
  • 7
    Chung RT, Andersen J, Volberding P et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451459.
  • 8
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438450.
  • 9
    Nunez M, Miralles C, Berdun MA et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23: 972982.
  • 10
    Ghany M, Nelson D, Strader D, Thomas D, Seeff L. An update on treatment of genotype 1 chronic hepatitis c virus infection: practice guideline by the american association for the study of liver diseases. Hepatology 2011; 54: 14331444.
  • 11
    Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 24052416.
  • 12
    Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 10141024.
  • 13
    Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 24172428.
  • 14
    Sulkowski MS, Sherman KE, Dieterich DT et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 8696.
  • 15
    Vallet-Pichard A, Mallet V, Nalpas B et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 3236.
  • 16
    Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 1.0 – December 2004 (Clarification dated August 2009). Available at (accessed 7 February 2013).
  • 17
    Mira JA, Garcia-Rey S, Rivero A et al. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Clin Infect Dis 2012; 55: 17191726.
  • 18
    Zeremski M, Dimova RB, Makeyeva J et al. IL28B polymorphism, pretreatment CXCL10 and HCV RNA levels predict treatment response in racially diverse HIV/HCV co-infected and HCV mono-infected patients. J Acquir Immune Defic Syndr 2012; 63: 916.
  • 19
    Cotte L, Braun J, Lascoux-Combe C et al. High Early Virological Response with Telaprevir-Pegylated-Interferon-Ribavirin in Treatment-experienced Hepatitis C Virus Genotype 1/HIV Co-infected Patients: ANRS HC26 TelapreVIH Study. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, March 2013.
  • 20
    Bichoupan K, Giannattasio E, Martel-Laferriere V et al. Side effects and adverse outcomes of telaprevir-based triple therapy in HCV-positive patients with and without advanced fibrosis: real life experience. Hepatology 2012; S1: 1010A.
  • 21
    INCIVEKTM (telaprevir) Film Coated Tablets, for oral use. Available at (accessed 29 August 2013).
  • 22
    Heeswijk R, Garg V, Boogaerts G et al. The Pharmacokinetic Interaction Between Telaprevir & Raltegravir in Healthy Volunteers. 51st ICAAC. Chicago, IL, September 2011 [Abstract A1-1738a].
  • 23
    Heeswijk R, Vandevoorde A, Boogaerts G et al. Pharmacokinetic Interactions between ARV Agents and the Investigational HCV Protease Inhibitor TVR in Healthy Volunteers. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2011 [Abstract 119].
  • 24
    Kakuda T, Leopold L, Nijs S et al. Telaprevir and Etravirine or Rilpivirine. 13th HIV PK Workshop. Barcelona, Spain, April 2012 [Abstract O-18].
  • 25
    Garg V, Chandorkar G, Yang Y et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol 2013; 75: 431439.
  • 26
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at (accessed 29 August 2013).
  • 27
    Reiss P, Battegay M, Clumeck N et al. European AIDS Cilnical Society Guidelines. Version 2011; 6: 160.
  • 28
    Victrelis (boceprevir) Capsules for oral use: Full prescribing information. Available at (accessed 29 August 2013).